Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor

Executive Summary

Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.

You may also be interested in...



Judge Rejects Prior Restraint For Tylenol Ads Ahead Of 'Bellwether' Trial

J&J/McNeil may continue to advertise the Tylenol line ahead of the first case in multi-district litigation claiming use of the products as labeled is linked to liver damage, says a federal judge. The plaintiff asked the court to prohibit the firm from advertising that could taint the juror pool ahead of the fall trial.

OTC Antacid/Aspirin Bleeding Risk Raises Concerns At CDER

CDER publishes a Drug Safety Communication, a consumer announcement and a MedWatch notice warning about the risk of serious bleeding when using OTC aspirin-containing antacid products.

OTC Acetaminophen Label Guidance For Liver Warning Clarifies Ingredient Specifics

FDA allows marketers of acetaminophen-containing OTC products to use an alternative liver warning, according to an updated guidance. The change from the draft, which aligns with a request by CHPA, separates maximum dosage for the ingredient from the dosage included in a certain product.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS119038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel